We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00184353
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : October 21, 2011
Sponsor:
Collaborator:
The Royal Norwegian Ministry of Health
Information provided by (Responsible Party):
Norwegian University of Science and Technology

Brief Summary:
Increasing magnetic field is known to give improvements in signal-to-noise-ratio (SNR) and spectral resolution. To investigate this, spectra from different subjects were examined using two clinical MR instruments operating at 1.5T and 3T respectively.

Condition or disease
Neoplasm Metastases

Study Type : Observational
Actual Enrollment : 19 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: In Vivo Proton MR Spectroscopy of Brain Metastases Obtained at 1,5T and 3T.
Study Start Date : November 2003
Primary Completion Date : December 2004
Study Completion Date : June 2005

Group/Cohort
brain metastases
6 patients
healthy
13 volunteers




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with brain metastases
Criteria

Inclusion Criteria:

  • brain metastases

Exclusion Criteria:

  • children
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184353


Locations
Norway
Norwegian University of Science and Technology
Trondheim, Norway, N-7489
Sponsors and Collaborators
Norwegian University of Science and Technology
The Royal Norwegian Ministry of Health
Investigators
Study Director: Steinar Lundgren, MD PhD Cancer Clinic, St.Olavs Hospital Trondheim University Hospital
Study Chair: Ingrid S Gribbestad, PhD Norwegian University of Science and Technology, Faculty of Medicine

Publications:
Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00184353     History of Changes
Other Study ID Numbers: 173-03
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: October 21, 2011
Last Verified: October 2011

Keywords provided by Norwegian University of Science and Technology:
brain metastasis
signal to noise ratio
spectral resolution

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplasms, Second Primary
Neoplastic Processes
Neoplasms
Pathologic Processes